This article first appeared on GuruFocus .
Release Date: July 31, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Indegene Ltd ( NSE:INDGN ) reported strong Q1 FY27 revenue of INR10,631 million, up 39.7% year-on-year and 6% quarter-on-quarter, marking the best first-quarter sequential growth in four years.
-
The company's client base crossed a milestone of 100 active customers, reaching 105, with revenue from accounts beyond the TOP20 now contributing over a third of total revenue, indicating successful diversification.
-
Revenue per employee reached approximately $77,000 on a trailing twelve-month basis, which management highlighted as industry-leading and a reflection of the productivity of its engagement model.
-
The company signed several strategic deals, including an expansion of the Tectonic engagement to Spain and a $10 million+ outcome-based omnichannel marketing deal with a top customer, which is expected to contribute to revenue starting Q3 FY27.
-
Management reiterated confidence in margin recovery, expecting EBITDA to return to the historical 19%-20% range by Q4 FY27, driven by revenue ramp-up from contracted deals and productivity benefits from workforce transformation and GenAI initiatives.
-
The company highlighted its 'Indegene Edge' (Embedded revenue partner, Domain expertise, GenAI disruptor, Engagement model), positioning it as structurally different from traditional IT services or agencies and resilient to cost-cutting.
-
Cash and cash equivalents combined with investments remained strong at INR14,602 million, and the company has strengthened its cash position by over 30% in the last two years.
Negative Points
-
EBITDA margin declined sequentially when adjusted for the prior quarter's one-time mark-to-market impact, due to investments in workforce transformation and costs related to contracted Tectonic and GenAI engagements where revenue contribution is still building slowly.
-
The company is carrying costs for the large outcome-based omnichannel engagement since Q4 FY26, with revenue recognition deferred until Q3 FY27, which will continue to pressure margins in the near term.
-
DSO (days sales outstanding) increased by four days quarter-on-quarter to 67 days, indicating a slight deterioration in receivables collection.
-
Enterprise adoption of AI remains measured and slower than the enthusiasm suggests, with the Tectonic engagement's offtake on existing scope being described as 'measured', indicating potential delays in revenue ramp-up.
-
The company faces ongoing risks from currency volatility, with undesignated hedges still material through December of this year, which could impact financial results despite moving to hedge accounting.
-
Management noted that smaller biotechs had a mixed first half, with funding and IPO conditions remaining selective, which could impact growth in that segment of the customer base.
-
The company is not breaking out organic vs. inorganic growth or AI-led platform revenue, making it difficult for investors to quantify the impact of specific strategic initiatives.
Q & A Highlights
-
Warning! GuruFocus has detected 5 Warning Signs with NSE:INDGN.
-
Is NSE:INDGN fairly valued? Test your thesis with our free DCF calculator.
Q: Could you clarify the margin trajectory? You mentioned H2 should normalize, but also mentioned Q4 for normalization. Is there a delay, and what gives you confidence that these expenses are true investments rather than ongoing costs? (Prolin Nandu, Edelweiss Public Alternatives) A: Manish Gupta (Chairman & CEO) clarified there is no delay. The initial guidance of six to eight quarters from October 2025 has been narrowed to six quarters, meaning margins will return to the 19%-20% range by Q4 FY27. He explained the investments are in strategic deals like Tectonic and a large US portfolio management engagement, where costs are incurred now but revenue visibility is strong for H2. Suhas Prabhu (CFO) added that the confidence comes from contracted revenue and the fact that these investments are not scaling with revenue.
Q: What are your top two to three execution priorities for the coming quarter, and what do you see as the biggest risk in client adoption, regulatory shifts, or competitive pressure? (Sukrit Patil, EyeSight FinTrade) A: Manish Gupta (Chairman & CEO) stated the priorities are converting the pipeline into revenue, especially from the largest clients, and getting the margin profile back on track. He noted the confidence is based on contracts already signed, not future wins. Suhas Prabhu (CFO) added that the biggest risk is the regulatory environment in the US, but the current policy outlook is stable, with drug pricing and MFN decisions largely behind the industry.
Q: What is the current portion of organic revenue growth, and can you provide a breakup of biopharma contribution? (Chirag Kachatia, Motilal Oswal Financial Services) A: Manish Gupta (Chairman & CEO) said the company no longer breaks out organic vs. inorganic growth or biopharma contribution, as biopharma is now well integrated into the business. Suhas Prabhu (CFO) noted that both are in the base sequentially.
Q: What was the constant currency growth for this quarter? (Vinay Menon, Monash Capital) A: Suhas Prabhu (CFO) explained that while the company discloses US dollar growth (2.5% QoQ), a quick approximation including Euro and GBP would put constant currency growth at around 2.6% to 2.7% QoQ.
Q: You talked about outcome-based deals. What percentage of your business is outcome-based, and is this the norm for scaling? Also, how does revenue and order book visibility flow through the P&L? (Prakash Kapadia, Kapadia Financial Services) A: Manish Gupta (Chairman & CEO) stated that approximately 60% of revenue is from output-plus-outcome-based contracts, a long-standing model. He noted the trend is expanding, especially with outcome-based deals linked to client revenue. Suhas Prabhu (CFO) explained that most engagements are hybrid, with FTE components starting quickly and output-based revenues ramping over three to four quarters. The large $10 million+ omnichannel deal is pure outcome-based, with revenue recognition deferred to Q3 FY27, and costs already incurred, so revenue will flow directly to the bottom line.
Q: Can you explain your proprietary GenAI model, including vertical ontology and integration with frontier or open-source models, given IP protection and cost pressures? (Varun Band, Plutos Investment) A: Manish Gupta (Chairman & CEO) detailed the strategy: a data infrastructure layer ("Indigene data universe"), the Cortex platform for knowledge engineering that separates SME and technical layers, and an agent layer with multiple agents for specific outcomes. The architecture is model-agnostic, iterating on frontier and open-weight models based on accuracy and cost. He noted a trend where larger pharma companies prefer on-prem open-weight models to protect data from frontier model providers.
Q: Can you quantify the percentage of revenue generated through AI-led platform engagements and how it will evolve? (Chandan Kumar, Narnolia Financial Services) A: Manish Gupta (Chairman & CEO) said the company cannot break this out because AI is embedded in everything they do, not a separate line of business. He emphasized a decade-long AI journey, with GenAI providing better tools to address the same problems of efficiency and effectiveness in pharma commercial and medical operations.
Q: You have given an EBITDA outlook to return to historical range by Q4. What are the key margin drivers other than costs already incurred? (Chandan Kumar, Narnolia Financial Services) A: Suhas Prabhu (CFO) identified the key drivers as the growth trajectory, investments in go-to-market and business leadership, and revenue uptake from contracted business like Tectonic. These costs will not increase in line with revenue, driving margin recovery.
Q: Are the deals you've been signing since listing incremental to the existing business, and what is the renewal base? (Chirag Kachatia, Motilal Oswal Financial Services) A: Manish Gupta (Chairman & CEO) confirmed the deals called out are net new business, not renewals. Suhas Prabhu (CFO) added that net retention has been more than 100%, with renewal cycles typically Jan-Dec and renegotiations every three to five years. The company has never lost a major enterprise deal in renewals.
Q: What are the key risks or challenges you anticipate in the coming quarter, and what measures are being taken to manage margins, cash flow, and balance sheet strength? (Sukrit Patil, EyeSight FinTrade) A: Suhas Prabhu (CFO) addressed currency volatility, noting the move to designated hedge accounting will reduce mark-to-market impacts. On receivables, he highlighted that over 90% of business comes from large, strong-balance-sheet pharma companies, with minimal bad debt historically. He also mentioned innovative deal structures for biotech clients and a focus on performance milestones in outcome-based contracts.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
